Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:AIM TSE:IAM TSE:OLY NYSEARCA:XLY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$0.34-39.7%$0.66$0.33▼$20.35$2.75M1.243.39 million shs3.23 million shsIAMIntegrated Asset ManagementC$0.00C$1.52▼C$2.92C$75.96MN/A30,209 shs8,780 shsOLYOlympia Financial GroupC$121.71-0.2%C$121.20C$103.24▼C$134.24C$292.83M0.3243221,972 shs1,410 shsXLYConsumer Discretionary Select Sector SPDR Fund$120.20+0.3%$113.90$100.71▼$125.01$23.23B1.2210.62 million shs6.05 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech+16.42%+7.69%+2.45%-50.88%-93.87%IAMIntegrated Asset Management0.00%0.00%0.00%0.00%0.00%OLYOlympia Financial Group-0.80%-0.41%+1.51%+5.18%+20.05%XLYConsumer Discretionary Select Sector SPDR Fund+0.01%+1.29%+11.24%+1.60%+20.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$0.34-39.7%$0.66$0.33▼$20.35$2.75M1.243.39 million shs3.23 million shsIAMIntegrated Asset ManagementC$0.00C$1.52▼C$2.92C$75.96MN/A30,209 shs8,780 shsOLYOlympia Financial GroupC$121.71-0.2%C$121.20C$103.24▼C$134.24C$292.83M0.3243221,972 shs1,410 shsXLYConsumer Discretionary Select Sector SPDR Fund$120.20+0.3%$113.90$100.71▼$125.01$23.23B1.2210.62 million shs6.05 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech+16.42%+7.69%+2.45%-50.88%-93.87%IAMIntegrated Asset Management0.00%0.00%0.00%0.00%0.00%OLYOlympia Financial Group-0.80%-0.41%+1.51%+5.18%+20.05%XLYConsumer Discretionary Select Sector SPDR Fund+0.01%+1.29%+11.24%+1.60%+20.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00BuyN/AN/AIAMIntegrated Asset Management 0.00N/AN/AN/AOLYOlympia Financial Group 3.00BuyC$167.4937.61% UpsideXLYConsumer Discretionary Select Sector SPDR Fund 2.69Moderate Buy$120.250.04% UpsideCurrent Analyst Ratings BreakdownLatest IAM, OLY, XLY, and AIM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/17/2026OLYOlympia Financial Group Fundamental ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuyC$167.49(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$90K30.60N/AN/A($2.99) per share-0.11IAMIntegrated Asset ManagementC$18.31M0.00N/A4.43C$0.67 per share0.00OLYOlympia Financial GroupC$98.10M2.99C$10.44 per share11.66C$18.47 per share6.59XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$13.96M-$24.68N/AN/AN/A-15,861.36%N/A-209.50%N/AIAMIntegrated Asset ManagementN/AC$0.1124.91N/AN/AN/AN/AN/AN/AOLYOlympia Financial GroupC$24.45MC$8.2514.75N/AN/A20.20%45.15%35.88%N/AXLYConsumer Discretionary Select Sector SPDR FundN/AN/A27.10N/AN/AN/AN/AN/AN/ALatest IAM, OLY, XLY, and AIM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2026Q4 2025AIMAIM ImmunoTechN/A-$0.4480N/A-$0.4480N/A$0.02 million2/28/2026Q4 2025OLYOlympia Financial GroupN/AC$1.83N/AC$1.83N/AC$24.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/AIAMIntegrated Asset ManagementC$0.114.38%N/A100.00%N/AOLYOlympia Financial GroupC$7.205.92%N/A87.27%N/AXLYConsumer Discretionary Select Sector SPDR Fund$0.890.74%N/AN/AN/ALatest IAM, OLY, XLY, and AIM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2026OLYOlympia Financial GroupMonthlyC$0.605.85%5/20/20265/29/20265/29/20264/21/2026OLYOlympia Financial GroupMonthlyC$0.605.99%4/21/20264/30/20264/30/20263/20/2026OLYOlympia Financial GroupMonthlyC$0.606.01%3/20/20263/31/20263/31/20262/18/2026OLYOlympia Financial GroupMonthlyC$0.606.08%2/18/20262/27/20262/27/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTechN/A0.530.53IAMIntegrated Asset ManagementN/A4.854.81OLYOlympia Financial Group13.18180.321.59XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%IAMIntegrated Asset ManagementN/AOLYOlympia Financial Group0.91%XLYConsumer Discretionary Select Sector SPDR Fund69.93%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.04%IAMIntegrated Asset ManagementN/AOLYOlympia Financial Group34.63%XLYConsumer Discretionary Select Sector SPDR FundN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech208.15 million8.15 millionNot OptionableIAMIntegrated Asset Management5627.72 millionN/ANot OptionableOLYOlympia Financial Group3252.41 millionN/ANot OptionableXLYConsumer Discretionary Select Sector SPDR Fund147,000193.26 millionN/ANot OptionableIAM, OLY, XLY, and AIM HeadlinesRecent News About These CompaniesConsumer Discretionary Select Sector SPDR Fund (NYSEARCA:XLY) Stock Price Passes Above 200 Day Moving Average - Here's WhyMay 2, 2026 | americanbankingnews.comWeekly Economic Snapshot: Resilience Amid Record Sentiment LowsApril 27, 2026 | etftrends.comEETFs to Watch as Tesla Shares Slump Despite Q1 Earnings BeatApril 24, 2026 | zacks.comMajor ETFs Face Tesla Earnings Test Amid AI PivotApril 22, 2026 | etftrends.comE4 Sector ETFs for 2Q 2026April 15, 2026 | zacks.comWeekly ETF flows: Four of 11 sectors record outflows; the technology sector leads inflowsApril 14, 2026 | msn.comShould You Invest in the State Street Consumer Discretionary Select Sector SPDR ETF (XLY)?April 14, 2026 | zacks.comWeekly Economic Snapshot: Geopolitical Tensions & Inflationary PressuresApril 13, 2026 | etftrends.comETop and lowest-rated consumer discretionary stocks as Q1 earnings season gets underwayApril 7, 2026 | msn.comWeekly ETF flows: Five of 11 sectors record outflows; energy sector leads inflowsApril 7, 2026 | seekingalpha.comMost and least shorted consumer discretionary stocks with over $2B market cap as of MarchApril 3, 2026 | msn.comConsumer Discretionary among laggards in Q1 amid sector weaknessApril 1, 2026 | seekingalpha.comWeekly Economic Snapshot: Erosion of Confidence & Extended Market LossesMarch 30, 2026 | etftrends.comESectors of the day: Consumer Discretionary and TechnologyMarch 23, 2026 | seekingalpha.comPulteGroup stock: Is PHM outperforming the consumer discretionary sector?March 13, 2026 | msn.comUS CPI Up 0.3% in February: Consumer Discretionary ETFs to WatchMarch 12, 2026 | zacks.com3 ETFs to Avoid as Oil Shock Hits Markets (XLY)...March 12, 2026 | marketbeat.com3 ETFs That Could Benefit as Consumers Tighten Their Budgets...March 11, 2026 | marketbeat.comDo More for Your Core: A Tactical Roadmap for Sector InvestingFebruary 26, 2026 | etftrends.comEHere's the Committee's discretionary playbookFebruary 24, 2026 | youtube.comYWeekly Economic Snapshot: Inflation Heat Meets a Cooling EconomyFebruary 23, 2026 | etftrends.comENew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026A Diamond Quality Entry in DIA ETF, or Is It Time to Get Out?By Thomas Hughes | April 17, 2026Up 775% in 5 Months, How Much Higher Can Syntec Optics Go?By Thomas Hughes | April 21, 2026How Williams Companies Is Cashing in on the AI Power BoomBy Chris Markoch | May 6, 2026Sherwin-Williams: The Boring Beauty Play on Housing RecoveryBy Chris Markoch | May 1, 2026IAM, OLY, XLY, and AIM Company DescriptionsAIM ImmunoTech NYSEAMERICAN:AIM$0.34 -0.22 (-39.66%) Closing price 04:10 PM EasternExtended Trading$0.36 +0.02 (+5.06%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Integrated Asset Management TSE:IAMIntegrated Asset Management Corp. operates as an alternative asset investment management company. The company provides investors with private equity, private corporate debt, managed futures, hedge funds, real estate investment management, property management and leasing, and merchant banking. It offers alternative asset class management to institutional, pension, and private clients. Integrated Asset Management Corp. was founded in 1998 and is headquartered in Toronto, Canada.Olympia Financial Group TSE:OLYC$121.71 -0.30 (-0.25%) As of 03:59 PM EasternOlympia Financial Group Inc. ("OFGI") conducts most of its operations through its subsidiary Olympia Trust Company, a non-deposit taking trust company. Olympia Trust Company is licensed to conduct trust activities in Alberta, British Columbia, Saskatchewan, Manitoba, Quebec, Newfoundland and Labrador, Prince Edward Island, New Brunswick, and Nova Scotia. Olympia Trust Company administers self-directed registered plan accounts, corporate trust, and transfer agency services. OFGI also provides currency exchange and global payment services through its subsidiary Olympia Currency and Global Payments Inc., and offers private health services plans and information technology services to exempt market dealers, registrants, and issuers through its subsidiary Olympia Benefits Inc. OFGI's common shares are listed on the Toronto Stock Exchange under the symbol "OLY".Consumer Discretionary Select Sector SPDR Fund NYSEARCA:XLY$120.20 +0.32 (+0.27%) Closing price 04:10 PM EasternExtended Trading$120.10 -0.09 (-0.08%) As of 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Consumer Discretionary Select Sector SPDR Fund seeks to provide investment results that correspond generally to the price and yield performance of the Consumer Discretionary Select Sector Index (the Index). The Index includes companies from the following industries, media; retail (specialty, multiline, Internet and catalog); hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure equipment and products; and diversified consumer services. The Fund's investment advisor is SSgA Funds Management, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
